Shares rocketed 83.3% to 7.79 after the FDA let Achillion Pharmaceuticals (ACHN) resume hepatitis C drug trials. The FDA halted a Sovaprevir study last July amid concern over dangerous liver-enzyme elevations. Achillion shares jumped nearly 48% Mon. as Merck's (MRK) deal to buy hep C drug developer Idenix Pharmaceuticals (IDIX) raised takeover buzz for Achillion.
- Health Care Industry
- Pharmaceuticals & Drug Trials